Home

Eli Lilly (LLY)

792.00
+20.25 (2.62%)
NYSE · Last Trade: Jul 16th, 12:37 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close771.75
Open773.50
Bid791.18
Ask792.75
Day's Range772.16 - 796.04
52 Week Range677.09 - 972.53
Volume1,714,517
Market Cap757.61B
PE Ratio (TTM)64.44
EPS (TTM)12.3
Dividend & Yield6.000 (0.76%)
1 Month Average Volume2,945,716

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · July 16, 2025
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'benzinga.com
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via Benzinga · July 16, 2025
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlookmarketbeat.com
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
Via MarketBeat · July 15, 2025
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.
Via AB Newswire · July 15, 2025
How Do Investors Really Feel About Eli Lilly?benzinga.com
Via Benzinga · July 15, 2025
This Is What Whales Are Betting On Eli Lillybenzinga.com
Via Benzinga · July 10, 2025
Palatin’s Oral Obesity Drug Shows Remarkable Results: The Hidden Gem in the Weight Loss Race
Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) may have just positioned itself as a serious contender in the rapidly expanding obesity treatment market with impressive new preclinical data for its oral MC4R agonist PL7737. The results, announced today, demonstrate both rapid weight loss as a standalone therapy and enhanced effects when combined with GLP-1 medications like tirzepatide.
Via AB Newswire · July 15, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · July 15, 2025
1 S&P 500 Stock for Long-Term Investors and 2 to Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · July 15, 2025
Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlookbenzinga.com
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.
Via Benzinga · July 14, 2025
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetesbenzinga.com
An update on Sana Biotechnology.
Via Benzinga · July 14, 2025
This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Saysbenzinga.com
Rocket Lab notched its fastest launch turnaround ever, completing its 68th Electron mission and signaling a new era of rocket deployment.
Via Benzinga · July 14, 2025
3 Dividend Growth Stocks to Buy and Holdfool.com
Via The Motley Fool · July 12, 2025
Market Whales and Their Recent Bets on LLY Optionsbenzinga.com
Via Benzinga · July 11, 2025
A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analystsbenzinga.com
Via Benzinga · July 11, 2025
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Leviesbenzinga.com
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via Benzinga · July 11, 2025
Eli Lilly And Company Stock: U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’stalkmarkets.com
Eli Lilly stock has risen over 400% in 5 years despite a recent pullback.
Via Talk Markets · July 10, 2025
Are Growth Stocks Back? 3 That Look Like Winners to Buy Nowmarketbeat.com
Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.
Via MarketBeat · July 10, 2025
3 Profitable Stocks Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Via StockStory · July 10, 2025
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lillyfool.com
Via The Motley Fool · July 9, 2025
Zepbound Powers Eli Lilly's Upbeat Q2 Outlookbenzinga.com
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady.
Via Benzinga · July 9, 2025
Elon Musk-Led SpaceX Starlink Gets Final Regulatory Approval For Launch In India: Reportstocktwits.com
Reuters reported on Wednesday, citing three sources, that Starlink has cleared the only remaining regulatory hurdle for the satellite provider to enter the market.
Via Stocktwits · July 9, 2025
FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatmentbenzinga.com
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid plaque reduction.
Via Benzinga · July 9, 2025
Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effectsstocktwits.com
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less pathologically advanced in their disease.
Via Stocktwits · July 9, 2025
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'stocktwits.com
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.
Via Stocktwits · July 8, 2025